drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous CAR T-cell product designed to recognize both CD20 and CD30 antigens to mediate MHC-independent cytotoxicity against CD20-positive or CD20/CD30 double-positive lymphomas, including post–CD19 CAR T relapse.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with a bispecific chimeric antigen receptor that binds CD20 and CD30 on malignant cells, triggering MHC-independent T-cell activation, cytokine release, and cytotoxic killing of CD20+ or CD20/CD30+ lymphomas, helping prevent antigen escape after CD19-directed therapy.
drug_name
Bispecific anti-CD20/CD30 CAR T cells
nct_id_drug_ref
NCT06756321